Detalhe da pesquisa
1.
Sustained remissions in CLL after frontline FCR treatment with very-long-term follow-up.
Blood
; 142(21): 1784-1788, 2023 11 23.
Artigo
Inglês
| MEDLINE | ID: mdl-37595283
2.
Growth dynamics in naturally progressing chronic lymphocytic leukaemia.
Nature
; 570(7762): 474-479, 2019 06.
Artigo
Inglês
| MEDLINE | ID: mdl-31142838
3.
Global miRNA profiling reveals key molecules that contribute to different chronic lymphocytic leukemia incidences in Asian and Western populations.
Haematologica
; 109(2): 479-492, 2024 Feb 01.
Artigo
Inglês
| MEDLINE | ID: mdl-37646669
4.
STAT3 Activates the Pentraxin 3 Gene in Chronic Lymphocytic Leukemia Cells.
J Immunol
; 208(12): 2847-2855, 2022 06 15.
Artigo
Inglês
| MEDLINE | ID: mdl-35595309
5.
A phase 1 study to evaluate the safety, pharmacology, and feasibility of continuous infusion nelarabine in patients with relapsed and/or refractory lymphoid malignancies.
Cancer
; 129(4): 580-589, 2023 02 15.
Artigo
Inglês
| MEDLINE | ID: mdl-36448227
6.
Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemia.
Blood
; 133(10): 1011-1019, 2019 03 07.
Artigo
Inglês
| MEDLINE | ID: mdl-30530801
7.
Minimal residual disease undetectable by next-generation sequencing predicts improved outcome in CLL after chemoimmunotherapy.
Blood
; 134(22): 1951-1959, 2019 11 28.
Artigo
Inglês
| MEDLINE | ID: mdl-31537528
8.
STAT3-Induced Wnt5a Provides Chronic Lymphocytic Leukemia Cells with Survival Advantage.
J Immunol
; 203(11): 3078-3085, 2019 12 01.
Artigo
Inglês
| MEDLINE | ID: mdl-31645416
9.
Inferring clonal heterogeneity in cancer using SNP arrays and whole genome sequencing.
Bioinformatics
; 35(17): 2924-2931, 2019 09 01.
Artigo
Inglês
| MEDLINE | ID: mdl-30689715
10.
A pilot study of lower doses of ibrutinib in patients with chronic lymphocytic leukemia.
Blood
; 132(21): 2249-2259, 2018 11 22.
Artigo
Inglês
| MEDLINE | ID: mdl-30254130
11.
Correction: Novel Role of NOX in Supporting Aerobic Glycolysis in Cancer Cells with Mitochondrial Dysfunction and as a Potential Target for Cancer Therapy.
PLoS Biol
; 15(12): e1002616, 2017 12.
Artigo
Inglês
| MEDLINE | ID: mdl-29227990
12.
Time-to-progression after front-line fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy for chronic lymphocytic leukaemia: a retrospective, multicohort study.
Lancet Oncol
; 20(11): 1576-1586, 2019 11.
Artigo
Inglês
| MEDLINE | ID: mdl-31582354
13.
Routine sequencing in CLL has prognostic implications and provides new insight into pathogenesis and targeted treatments.
Br J Haematol
; 185(5): 852-864, 2019 06.
Artigo
Inglês
| MEDLINE | ID: mdl-30924136
14.
The involvement of microRNA in the pathogenesis of Richter syndrome.
Haematologica
; 104(5): 1004-1015, 2019 05.
Artigo
Inglês
| MEDLINE | ID: mdl-30409799
15.
Ibrutinib Therapy Increases T Cell Repertoire Diversity in Patients with Chronic Lymphocytic Leukemia.
J Immunol
; 198(4): 1740-1747, 2017 02 15.
Artigo
Inglês
| MEDLINE | ID: mdl-28077600
16.
Toward the potential cure of leukemias in the next decade.
Cancer
; 124(22): 4301-4313, 2018 11 15.
Artigo
Inglês
| MEDLINE | ID: mdl-30291792
17.
Results of second salvage therapy in 673 adults with acute myelogenous leukemia treated at a single institution since 2000.
Cancer
; 124(12): 2534-2540, 2018 06 15.
Artigo
Inglês
| MEDLINE | ID: mdl-29645075
18.
The absolute percent deviation of IGHV mutation rather than a 98% cut-off predicts survival of chronic lymphocytic leukaemia patients treated with fludarabine, cyclophosphamide and rituximab.
Br J Haematol
; 180(1): 33-40, 2018 01.
Artigo
Inglês
| MEDLINE | ID: mdl-29164608
19.
Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia.
Blood
; 127(3): 303-9, 2016 Jan 21.
Artigo
Inglês
| MEDLINE | ID: mdl-26492934
20.
Ibrutinib efficacy and tolerability in patients with relapsed chronic lymphocytic leukemia following allogeneic HCT.
Blood
; 128(25): 2899-2908, 2016 12 22.
Artigo
Inglês
| MEDLINE | ID: mdl-27802969